Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for the treatment of rare diseases. Headquartered in San Diego, California, the company's primary focus is on Duchenne muscular dystrophy (DMD) and other conditions characterized by inflammation, fibrosis, and tissue degeneration. Its lead product candidate, Deramiocel (CAP-1002), is an allogeneic cardiac-derived cell therapy that has advanced to late-stage clinical development for DMD. In addition to its cell therapy programs, Capricor is developing its proprietary StealthX exosome platform for targeted delivery of oligonucleotides, proteins, and small molecule therapeutics, as well as for vaccine development. The company has established strategic partnerships, including an exclusive commercialization and distribution agreement with Nippon Shinyaku for Deramiocel in the United States and Japan.
